Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
Open accessThe DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Abstract
Genetic studies have shown that the tuberous sclerosis complex (TSC) 1–TSC2–mammalian target of Rapamycin (mTOR) and the Hippo–Yes-associated protein 1 (YAP) pathways are master regulators of organ size, which are often involved in tumorigenesis. The crosstalk between these signal transduction pathways in coordinating environmental cues, such as nutritional status and mechanical constraints, is crucial for tissue growth. Whether and how mTOR regulates YAP remains elusive. Here we describe a novel mouse model of TSC which develops renal mesenchymal lesions recapitulating human perivascular epithelioid cell tumors (PEComas) from patients with TSC. We identify that YAP is up-regulated by mTOR in mouse and human PEComas. YAP inhibition blunts abnormal proliferation and induces apoptosis of TSC1–TSC2-deficient cells, both in culture and in mosaic Tsc1 mutant mice. We further delineate that YAP accumulation in TSC1/TSC2-deficient cells is due to impaired degradation of the protein by the autophagosome/lysosome system. Thus, the regulation of YAP by mTOR and autophagy is a novel mechanism of growth control, matching YAP activity with nutrient availability under growth-permissive conditions. YAP may serve as a potential therapeutic target for TSC and other diseases with dysregulated mTOR activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Cross-talk also exists between Tsc1 and Tsc2 and the Hippo effector Yap as Tsc1/2-deficient cells have higher Yap levels due to less Yap degradation via the autophagosome system (83).”
From The Hippo signal transduction network for exercise physiologists (2016) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Autophagy: Renovation of Cells and Tissues
Mizushima, N., & Komatsu, M. (2011) · Cell · doi:10.1016/j.cell.2011.10.026 · Cited by 6,418
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Regulation mechanisms and signaling pathways of autophagy
He, C., & Klionsky, D. J. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102808-114910 · Cited by 3,609 · cited 1×
“…mTORC1 inhibits the initiation of autophagy, which is a eukaryotic catabolic pathway that sequesters cellular organelles and proteins in double-membrane autophagosomes, and delivers and degrades the cargos in lysosomes (He and Klionsky, 2009; Mizushima and Komatsu, 2011; Choi et al., 2013).”
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 1×
“It is mainly through heterodimeric GTPases RagA/B and RagC/D, which were anchored to lysosomes through Ragulator protein complex (Lamtor1-5) and v-ATPase (Sancak et al., 2010; Sancak et al., 2008; Zoncu et al., 2011).”
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653 · cited 1×
“differentiate into adipocytes and smooth muscle cells in vitro, which are two major components commonly observed in angiomyolipomas (Armulik et al., 2011).”
Autophagy in Human Health and Disease
Choi, A. M. K., Ryter, S. W., & Levine, B. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1205406 · Cited by 2,583
Cited by
Items 201–219 of 219
Li, Y.-S., Liu, W., Yu, H.-D., Zuo, Z., & Liu, X.-Z. (2025) · Open Life Sciences · doi:10.1515/biol-2022-0970
He, T., Zeng, Y., Zhou, J., Tian, Y., Wang, D., Ma, J., Liu, J., Wu, W., Wei, C., & Jiao, R. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116922
Bhat, M. A., Mushtaq, I., & Raja, W. Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-23908-3.00007-1
Corvaisier, M. (2016) · theses.fr (ABES) · doi:10.70675/8162a0d3z7fa2z4d40zb097z7fd0055b3a75
Tuberous sclerosis complex : molecular target of mTORC1 and the role of S6Ks
Bonucci, M. (2019) · theses.fr (ABES) · doi:10.70675/fd5e0059z9c7bz468ezb8bdz4c2214da80c2
Control of the invadopodia/MT1-MMP axis by mTORC1/TFEB signaling pathway in breast cancer cells
Remy, D. (2022) · theses.fr (ABES) · doi:10.70675/849dc96dz8e18z4428zbf6fz67c9b1d98114
sPRR Signaling in Macrophages via the AT1R/Yap/Taz Axis to Induce Renal FibrosisPreprint
Feng, Y., Zheng, H., Xie, S., Wang, F., Luo, R., & Yang, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.03.716436
Duclos, M. (2023) · theses.fr (ABES) · doi:10.70675/cddf5dbaz5c2bz4a63z98f1zb600c3ecd191
Role of brain somatic mutations in epileptogenic malformations
Sami, L. (2024) · theses.fr (ABES) · doi:10.70675/a5203ae5zaabez4145zb59fzd7cf74e18443
Li, H., Xing, W., Dai, Y., Cao, S., Yang, X., Zhang, Y., Zeng, X., Liu, H., & Wu, X. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.04.028
Aprile, M., Callegari, V., Cipri, S., Nunno, V. D., Gatto, L., Tosoni, A., Dima, G., Argento, C. M., Bartolini, S., Margotti, M., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105417
Zhang, L., Lu, Y., Liu, D., & Sheng, B. (2026) · The Journal of Gene Medicine · doi:10.1002/jgm.70101
mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC)
Li, K., Du, H., Wang, Y., Khabibullin, D., Alchoueiry, M., Daou, M., Asara, J. M., Kwiatkowski, D. J., Henske, E. P., & Liu, H.-J. (2026) · Oncogene · doi:10.1038/s41388-026-03891-w
Self-citationCancer Predisposition Syndromes
Cipri, S., Zinicola, T., Boccuto, L., Colafati, G. S., D’Antonio, F., D’Orazio, C., Agolini, E., & Mastronuzzi, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-18992-9_5
Vilioti, M. S., Ragnelli, B. C., Berling, F. P., Mendes, C. M., Assumpção, M. E. O. D., & Goissis, M. D. (2026) · Reproductive Biology · doi:10.1016/j.repbio.2026.101284
CATALYTIC-INDEPENDENT FUNCTIONS OF KDM6A IN B CELL MATURATION AND IMMUNE REGULATION
Casola, S. S., Costanzo, V., Pasini, D., & Ranise, C. (2025) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)
Wang, X., Chen, L., 朱顺田, Zhang, Y., & Liu, Y. (2026) · Vessel Plus · doi:10.20517/2574-1209.2026.24
Bertolini, F. (n.d.) · Institutional Research Information System University of Turin (University of Turin)
Metadata
- Authors
- Liang, N., Zhang, C., Dill, P., Panasyuk, G., Pion, D., Koka, V., Gallazzini, M., Olson, E. N., Lam, H., Henske, E. P., Dong, Z., Apte, U., Pallet, N., Johnson, R. L., Terzi, F., Kwiatkowski, D. J., Scoazec, J.-Y., Martignoni, G., & Pende, M.
- Affiliations
- Inserm (FR)
- The University of Texas Southwestern Medical Center (US)
- Brigham and Women's Hospital (US)
- Charlie Norwood VA Medical Center (US)
- University of Kansas Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Hospices Civils de Lyon (FR)
- University of Verona (IT)
- Corresponding author
- Pende, Mario
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-10-06
- Volume
- 211
- Issue
- 11
- Pages
- 2249-2263
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4203941
- OpenAlex
- W2111900780
- Cited by
- 205
- References
- 122
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 13 · 2023: 14 · 2022: 23 · 2021: 24 · 2020: 23 · 2019: 24 · 2018: 19 · 2017: 17 · 2016: 13 · 2015: 15 · 2014: 1
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Association pour la Recherche sur le Cancer
- Institut National de la Santé et de la Recherche Médicale
- China Scholarship Council
- Institut National Du Cancer
- National Cancer Institute (P01CA120964)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK096556)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- tuberous sclerosis complex, YAP, mTOR, autophagy, Hippo signaling pathway, PEComa, TSC1, TSC2, protein degradation, lysosomes, organ size control, therapeutic target, tumor growth control
- MeSH terms
- Tuberous Sclerosis Complex 1 Protein, Verteporfin, YAP-Signaling Proteins, Animals, Autophagy, Cell Survival, Disease Models, Animal, Gene Expression Regulation, Humans, Immunohistochemistry, Kidney, Phosphoproteins, Porphyrins, Tuberous Sclerosis, Signal Transduction, Up-Regulation, Apoptosis, Angiomyolipoma, Mice, Knockout, Cell Cycle Proteins, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.